As President, Operations, Steffen Lang leads a team of more than 25 000 associates dedicated to manufacturing and supplying high-quality medicines to patients, and providing operational support with latest technology and business solutions to the entire Novartis enterprise. Operations at Novartis incorporates the company’s manufacturing, quality, and supply organization, as well as information technology, data and digital, procurement, environmental sustainability, facility services, and global business services.
Victor Bulto
President, US, since April, 2022
Au cours des cinq dernières années, M. Vas a concentré l’accent mis sur des domaines thérapeutiques et des plateformes technologiques clés, notamment les siRNA, les radioligands et les thérapies géniques et cellulaires, afin de fournir de nouveaux médicaments aux patients atteints de maladies cardiovasculaires, de cancer et de maladies génétiques rares mais débilitantes. En parallèle, il a mené une transformation pour faire de la culture un moteur d’innovation, de réputation et de performance chez Novartis, tout en faisant avancer une révolution numérique pour utiliser la science des données et la technologie pour trouver de nouvelles façons de découvrir et de développer
Sessions Biography
As President, Development and Chief Medical Officer for Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline of investigational medicines and overseeing medical activities across the company to bring meaningful new treatment options to patients.
session-1
Development and Chief Medical Officer for Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline
session-2
session-3
Shreeram’s organization leads the development of potential new medicines, running large clinical trials and steering
session-4
high-value treatments for cardiovascular, renal and immunological conditions, neurological disorders
session-5
Shreeram is passionate about partnering with patients and physicians to change medical practice, recognizing